Deal Watch: Genentech Gets Access To X-Chem’s DNA-Encoded Library Technology
Genentech will use the X-Chem platform to obtain leads against multiple oncology targets. Lilly partners with Merus on CD3-targeting T-cell therapy candidates.
You may also be interested in...
The strategy for both funds is to back companies with a preclinical drug candidate that can be advanced through clinical proof-of-concept with a mid-sized series A round.
Priced at a 50% premium to GW’s value, the deal will reduce the percentage of Jazz’s drug sales coming from Xyrem, provide double-digit revenue growth and expand the R&D pipeline to 19 programs.
The US giant is taking a stake in Imcyse and taking over a program to develop RA drugs in a deal that validates the Belgian group's imotope technology.